Exact Sciences and National Surgical Adjuvant Breast and Bowel Project announce study

Madison-headquartered Exact Sciences Corp. announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative group founded by the National Cancer Institute. Together, Exact Sciences and the NSABP will conduct a prospective, multicenter validation study with stage II and III colorectal cancer patients, demonstrating the ability of Exact Sciences’ ctDNA test to detect MRD. The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the U.S. and Canada.